Taysha Gene Therapies (TSHA) Operating Leases (2022 - 2026)

Taysha Gene Therapies has reported Operating Leases for 5 years, with the latest figure at $17.8 million in Q1 2026.

• Quarterly Operating Leases rose 3.94% year-over-year to $17.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $17.8 million (up 3.94% YoY) and the FY2025 annual result came in at $18.2 million, up 4.67% from the prior year.
• Operating Leases slipped to $17.8 million in Q1 2026 per TSHA's latest filing, from $18.2 million in the prior quarter.
• Over five years, Operating Leases peaked at $20.4 million in Q4 2022 and troughed at $16.5 million in Q3 2025.
• A 5-year average of $18.3 million and a median of $18.2 million in 2024 frame the typical range for Operating Leases.
• The sharpest annual moves came in 2024 and 2025: Operating Leases dropped 8.4% in 2024, then increased 4.67% in 2025.
• Over 5 years, Operating Leases stood at $20.4 million in 2022, then fell by 7.27% to $19.0 million in 2023, then retreated by 8.4% to $17.4 million in 2024, then increased by 4.67% to $18.2 million in 2025, then retreated by 2.23% to $17.8 million in 2026.
• According to Business Quant data, Operating Leases over the past three periods registered $17.8 million, $18.2 million, and $16.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.